European Archives - Page 15 of 1607 - European Medical Journal

exons and introns

Amivantamab Extends Survival in Advanced NSCLC: WCLC 2026

Final PAPILLON data showed that first-line amivantamab chemotherapy extended median overall survival by more than 6 months in advanced EGFR Ex20ins NSCLC.

lung cancer care

Osimertinib Sustains Long-Term Survival Benefit in NSCLC: WCLC 2026

Eight-year ADAURA data showed sustained overall survival benefits with adjuvant osimertinib in patients with resected EGFR-mutated NSCLC.

cognitive ability

MRI Surveillance Improves Cognitive Outcomes in SCLC: WCLC 2026

An international phase III trial found that MRI surveillance alone improved cognitive failure free survival in patients with SCLC compared with PCI.

Maternal Cardiovascular Inequalities Widen with Age

Age-related maternal cardiovascular risk rises more sharply among Black women, a study of 1.9 million births shows.

Mohs Surgery Shows Similar Five-Year CSCC Recurrence Rates

MMS showed no significant difference in five-year CSCC recurrence versus standard excision, while producing smaller surgical defects.

Difficult-to-Manage Axial Spondyloarthritis: Rare, But High-Burden

A 10-year study of 177 axial spondyloarthritis patients found difficult-to-manage disease was rare but carried a high socio-economic burden.

Antisecretory Factor Reduces Mortality in Severe TBI Trial

Antisecretory factor significantly reduced mortality in severe TBI patients in a phase II trial. Discover what this could mean for future care.

Advancing LGBTQIA+ Healthcare

In this series, host Catherine Glass speaks with Linda Wesp about advancing LGBTQIA+ healthcare through gender-affirming care, culturally…

Interview: Natasha Rolls Discusses the Future of Specialist Stoma Care

For lots of complex reasons related to the unique landscape of stoma care, and because nurses generally aren’t very good at shouting about…

Dupilumab Efficacy in ABPA With Asthma - EMJ

Dupilumab Improves Lung Function in ABPA with Asthma

A phase 2 trial found that dupilumab improved lung function, reduced severe respiratory exacerbations and decreased systemic corticosteroid use in patients with asthma and ABPA.